A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT ID: NCT06568861

Last Updated: 2025-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-14
• Study Completion Date: 2025-07-28

Brief Summary

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.

Conditions

COVID-19

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Subjects with Moderate Hepatic Impairment (Child-Pughs Class B)

Subjects with moderate hepatic impairment will receive oral doses of 200 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.

Group Type: EXPERIMENTAL

ALG-097558

Intervention Type: DRUG

Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)

Subjects with Normal Hepatic Function

Subjects with normal hepatic function will receive oral doses of 200 mg ALG-097558 twice daily (every 12 hours \[Q12H\]) for 6 days for 11 total doses.

Group Type: EXPERIMENTAL

ALG-097558

Intervention Type: DRUG

Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)

Interventions

ALG-097558

Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and Female between 18 and 75 years old

2. BMI 17.5 to 40.0 kg/m^2 and a total body weight >50 kg (110 lb) 3 .Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non-sterile, male sexual partners agree to use highly effective contraceptive therapy

4. Female subjects must have a negative serum pregnancy test at screening

1. Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs and 12-lead electrocardiogram (ECG) assessment

2. Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, gender

3. Normal hepatic function with no known or suspected hepatic impairment

1. Subject satisfies the criteria for Class B of the Child-Pugh classification (Child Pugh Scores 7-9 points) within 28 days of study drug administration

2. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, Fibroscan, computerized tomography scan, or magnetic resonance imaging (MRI)

3. Stable hepatic impairment for at least 3 months prior to screening or second screening visit to demonstrate stability

4. Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening

5. Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria

Exclusion Criteria

1. Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results' interpretation

2. Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or clinical evidence at screening of significant or unstable cardiac disease etc.

3. Subjects with a history of clinically significant drug allergy

4. Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use

5. Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men

6. Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up

7. Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection. Subejcts with Hepatitis B infection may be eligible for moderate impairment cohort provided provided they met stable treatment criteria. Subjects with HIV infection may be eligible for moderate impairment cohort provided they met stable treatment criteria.

1. Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless otherwise instructed by the Study Review Committee (SRC), CKD-EPI should not be corrected for subjects of African ancestry

2. Bilirubin (total, direct) >1.2× upper limit of normal (ULN) (unless Gilbert's is suspected)

3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level > 1.2×ULN

4. Grade ≥1 Hemoglobin

1. Subjects with advanced ascites (Grade 3)

2. Subjects with refractory encephalopathy as judged by the investigator.

3. Subjects with esophageal variceal bleeding within the past 6 months prior to screening.

4. Subjects with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement.

5. Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless otherwise instructed by the SRC, CKD-EPI should not be corrected for subjects of African ancestry

6. ALT or AST level ≥5×ULN

7. Serum sodium ≤125 mmol/L

8. Platelets <50×10^9/L

9. Grade ≥2 Hemoglobin

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Aligos Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Miami

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Countries

United States

Other Identifiers

ALG-097558-702 / DMID 24-0001

Identifier Type: -

Identifier Source: org_study_id